These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 31776787)

  • 1. Leukemic Non-nodal Mantle Cell Lymphoma: Diagnosis and Treatment.
    Jain AG; Chang CC; Ahmad S; Mori S
    Curr Treat Options Oncol; 2019 Nov; 20(12):85. PubMed ID: 31776787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From the archives of MD Anderson Cancer Center: Untreated leukemic non-nodal mantle cell lymphoma with relapse as pleomorphic variant mantle cell lymphoma 21 years later.
    Fang H; Medeiros LJ; Tang Z; Wang W; Ok CY; Patel KP; Khoury JD; Thakral B
    Ann Diagn Pathol; 2021 Feb; 50():151649. PubMed ID: 33189964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pathologic diagnosis of mantle cell lymphoma.
    Li S; Xu J; You MJ
    Histol Histopathol; 2021 Oct; 36(10):1037-1051. PubMed ID: 34114641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2017 Aug; 92(8):806-813. PubMed ID: 28699667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent Presentation of Hairy Cell Leukemia and Mantle Cell Lymphoma (Leukemic Non-Nodal Variant): An Extremely Rare Composite Lymphoma.
    Soliman DS; Ibrahim F; Fernyhough LJ; Murad F; Akiki S
    J Hematol; 2022 Feb; 11(1):21-28. PubMed ID: 35356636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smoldering mantle cell lymphoma.
    Ye H; Desai A; Zeng D; Nomie K; Romaguera J; Ahmed M; Wang ML
    J Exp Clin Cancer Res; 2017 Dec; 36(1):185. PubMed ID: 29246179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indolent mantle cell lymphoma.
    Hsi ED; Martin P
    Leuk Lymphoma; 2014 Apr; 55(4):761-7. PubMed ID: 23927395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage.
    Soleimani A; Navarro A; Liu D; Herman SEM; Chuang SS; Slavutsky I; Narbaitz M; Safah H; Schmieg J; Lefante J; Roschewski M; Wilson WH; Wiestner A; Saba NS
    Leuk Lymphoma; 2022 Apr; 63(4):911-917. PubMed ID: 34781807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop.
    Kahl BS; Dreyling M; Gordon LI; Martin P; Quintanilla-Martinez L; Sotomayor EM
    Leuk Lymphoma; 2019 Aug; 60(8):1853-1865. PubMed ID: 30696305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular profiling and management of mantle cell lymphoma.
    Ruan J
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):30-40. PubMed ID: 31808882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.
    Sakhdari A; Ok CY; Patel KP; Kanagal-Shamanna R; Yin CC; Zuo Z; Hu S; Routbort MJ; Luthra R; Medeiros LJ; Khoury JD; Loghavi S
    Ann Diagn Pathol; 2019 Aug; 41():38-42. PubMed ID: 31132650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.
    Condoluci A; Rossi D; Zucca E; Cavalli F
    Curr Oncol Rep; 2018 Aug; 20(10):79. PubMed ID: 30132080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How I manage mantle cell lymphoma: indolent versus aggressive disease.
    Wilson MR; Barrett A; Cheah CY; Eyre TA
    Br J Haematol; 2023 Apr; 201(2):185-198. PubMed ID: 36807902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemic non-nodal mantle cell lymphomas have a distinct phenotype and are associated with deletion of PARP1 and 13q14.
    Gallo M; Cacheux V; Vincent L; Bret C; Tempier A; Guittard C; Macé A; Leventoux N; Costes V; Szablewski V
    Virchows Arch; 2016 Dec; 469(6):697-706. PubMed ID: 27605053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mantle Cell Lymphoma Under the Scope of Personalized Medicine: Perspective and Directions.
    Gallucci Figorelle L; Galvão PT; de Lima FMR; Marimon P; Pentagna N; Milito C; Schaffel R; Carneiro K
    Clin Lymphoma Myeloma Leuk; 2024 Jul; 24(7):433-445. PubMed ID: 38641485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressive leukemic non-nodal mantle cell lymphoma associated with deletions of TP53, ATM, and/or 13q14.
    Chapman-Fredricks J; Sandoval-Sus J; Vega F; Lossos IS
    Ann Diagn Pathol; 2014 Aug; 18(4):214-9. PubMed ID: 24852242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference.
    Dreyling M; Hoster E; Bea S; Hartmann E; Horn H; Hutter G; Salaverria I; Pott C; Trneny M; Le Gouill S; Cortelazzo S; Szymczyk M; Jurczak W; Shpilberg O; Ribrag V; Hermine O;
    Leuk Lymphoma; 2010 Sep; 51(9):1612-22. PubMed ID: 20629519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.